J&J MedTech sales miss estimates as Abiomed weakness slows cardiovascular growth

Earnings
โดย Zacks Investment Research·Read original
Summary · why it matters

Johnson & Johnson's MedTech segment posted second-quarter sales of $8.93 billion, up 4.5 percent but slightly below the Zacks Consensus Estimate of $8.96 billion, as slower cardiovascular performance weighed on results. Operational growth in the Cardiovascular business was 3.1 percent, held back by a 2 percent decline in Abiomed sales after a U.K. study prompted physicians to reassess use of the Impella heart pump, while Shockwave revenues rose 14.6 percent to $335 million and electrophysiology sales increased 3.1 percent amid competitive pulsed field ablation pressures. The other three MedTech businesses all accelerated, with Surgery up 3.9 percent, Orthopedics up 4.9 percent, and Vision up 6 percent. J&J tempered its Abiomed outlook, now expecting only modest growth in the second half of 2026, but remains optimistic about overall MedTech performance driven by strength in Vision, Orthopedics, Surgery, and new product launches including the recently approved OTTAVA robotic surgical system and the VARIPULSE pulsed field ablation system.

Impact on stocks 4

Robotics & Physical AI▲ · 2 stocks
Biotech & Genomic Medicine▼ · 1 stocks
Johnson & Johnson
JNJ
▼ NegativeDemandrelevance

J&J MedTech sales missed estimates due to Abiomed weakness after a UK study reduced Impella use, and J&J tempered Abiomed outlook.

Brain-Computer Interface▼ · 1 stocks
Boston Scientific Corp
BSX
▼ NegativeCompetitionrelevance

Boston Scientific competes in electrophysiology; article notes competitive pulsed field ablation pressures, which may affect Boston Scientific's market share.

© 2026 MarketDXNews